DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...

(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...